Bacterial coinfection and antibiotic resistance in hospitalized COVID-19 patients: a systematic review and meta-analysis

Abstract

Background: There were a few studies on bacterial coinfection in hospitalized COVID-19 patients worldwide. This systematic review aimed to provide the pooled prevalence of bacterial coinfection from published studies from 2020 to 2022. Methods: Three databases were used to search the studies, and 49 studies from 2,451 identified studies involving 212,605 COVID-19 patients were included in this review. Results: The random-effects inverse-variance model determined that the pooled prevalence of bacterial coinfection in hospitalized COVID-19 patients was 26.84% (95% CI [23.85–29.83]). The pooled prevalence of isolated bacteria for Acinetobacter baumannii was 23.25% (95% CI [19.27–27.24]), Escherichia coli was 10.51% (95% CI [8.90–12.12]), Klebsiella pneumoniae was 15.24% (95% CI [7.84–22.64]), Pseudomonas aeruginosa was 11.09% (95% CI [8.92–13.27]) and Staphylococcus aureus (11.59% (95% CI [9.71–13.46])). Meanwhile, the pooled prevalence of antibiotic-resistant bacteria for extended-spectrum beta-lactamases producing Enterobacteriaceae was 15.24% (95% CI [7.84–22.64]) followed by carbapenem-resistant Acinetobacter baumannii (14.55% (95% CI [9.59–19.52%])), carbapenem-resistant Pseudomonas aeruginosa (6.95% (95% CI [2.61–11.29])), methicillin-resistant Staphylococcus aureus (5.05% (95% CI [3.49–6.60])), carbapenem-resistant Enterobacteriaceae (4.95% (95% CI [3.10–6.79])), and vancomycin-resistant Enterococcus (1.26% (95% CI [0.46–2.05])). Conclusion: All the prevalences were considered as low. However, effective management and prevention of the infection should be considered since these coinfections have a bad impact on the morbidity and mortality of patients.